BOSTON, August 7, 2025 — Leads & Copy — Elicio Therapeutics, Inc. (Nasdaq: ELTX) reported positive news regarding its ELI-002 7P randomized Phase 2 study in pancreatic cancer. The Independent Data Monitoring Committee (IDMC) recommended continuing the study without modifications to the final analysis. The final analysis, focused on disease-free survival (DFS), is expected in Q4 2025.
Elicio secured $10 million in financing in Q2 2025, and its current cash position is expected to support operations beyond the anticipated AMPLIFY-7P Phase 2 final analysis. The company also announced financial results for the second quarter ended June 30, 2025, with R&D expenses at $7.0 million and G&A expenses at $3.1 million. Net loss for the quarter was $10.6 million, and cash and cash equivalents as of June 30, 2025, were $22.1 million.
Robert Connelly, CEO of Elicio Therapeutics, expressed optimism about the IDMC’s recommendation, indicating preliminary signals of efficacy from ELI-002 7P in treating pancreatic ductal adenocarcinoma (PDAC). The company is focused on advancing clinical preparations for a potential pivotal Phase 3 trial and plans to request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the ELI-002 Phase 3 study.
Brian Ritchie, LifeSci Advisors, (212) 915-2578, britchie@lifesciadvisors.com
Source: Elicio Therapeutics
